Cart
sales@molnova.com
Cucurbitacin IIA
CAS No. 58546-34-2
Cucurbitacin IIA( —— )
Catalog No. M18849 CAS No. 58546-34-2
Cucurbitacin IIA can induce apoptosis and enhance autophagy, contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 58 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 192 | In Stock |
|
| 50MG | 287 | In Stock |
|
| 100MG | 428 | In Stock |
|
| 500MG | 888 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCucurbitacin IIA
-
NoteResearch use only, not for human use.
-
Brief DescriptionCucurbitacin IIA can induce apoptosis and enhance autophagy, contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases.
-
DescriptionCucurbitacin IIA can induce apoptosis and enhance autophagy , contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases. Cucurbitacin IIA is a novel class of anti-cancer drug in suppression of cancer cell expansion by disrupting the actin cytoskeleton and directing the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorSurvivin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number58546-34-2
-
Formula Weight562.74
-
Molecular FormulaC32H50O8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (44.43 mM)
-
SMILESCC(=O)OC(C)(C)CCC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3CC(C(C4(C)C)O)O)C)C)C)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SPD304
SPD304 is a selective TNF-α inhibitor and blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 μM for inhibiting in vitro TNF receptor 1 binding to TNF-α.
-
Utomilumab
Utomilumab (PF 05082566) is a humanized IgG2 antibody that targets the T-cell co-stimulatory receptor 4-1BB/CD137 and acts as a 4-1BB/CD137 agonist.
-
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.
